Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) EBITDA (2020 - 2023)

Cullinan Therapeutics has reported EBITDA over the past 4 years, most recently at -$45.5 million for Q4 2023.

  • Quarterly results put EBITDA at -$45.5 million for Q4 2023, down 39.49% from a year ago — trailing twelve months through Dec 2023 was -$173.5 million (down 219.93% YoY), and the annual figure for FY2025 was -$241.6 million, down 22.71%.
  • EBITDA for Q4 2023 was -$45.5 million at Cullinan Therapeutics, down from -$38.6 million in the prior quarter.
  • Over the last five years, EBITDA for CGEM hit a ceiling of $239.7 million in Q2 2022 and a floor of -$56.8 million in Q1 2023.
  • Median EBITDA over the past 4 years was -$29.5 million (2020), compared with a mean of -$9.2 million.
  • Peak annual rise in EBITDA hit 1553.13% in 2022, while the deepest fall reached 2499.49% in 2022.
  • Cullinan Therapeutics' EBITDA stood at -$29.2 million in 2020, then dropped by 14.15% to -$33.3 million in 2021, then rose by 2.06% to -$32.6 million in 2022, then plummeted by 39.49% to -$45.5 million in 2023.
  • The last three reported values for EBITDA were -$45.5 million (Q4 2023), -$38.6 million (Q3 2023), and -$32.6 million (Q2 2023) per Business Quant data.